Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(4.37)
# 1,199
Out of 4,339 analysts
497
Total ratings
45.2%
Success rate
8.1%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRVO CervoMed | Reiterated: Buy | $27 | $3.05 | +785.25% | 20 | May 19, 2026 | |
| BIIB Biogen | Reiterated: Buy | $245 | $193.08 | +26.89% | 82 | May 15, 2026 | |
| CLNN Clene | Reiterated: Buy | $50 | $6.57 | +661.04% | 12 | May 15, 2026 | |
| GHRS GH Research | Reiterated: Buy | $39 | $23.15 | +68.47% | 17 | May 15, 2026 | |
| MPLT MapLight Therapeutics | Reiterated: Buy | $35 | $29.46 | +18.81% | 2 | May 15, 2026 | |
| CMPS COMPASS Pathways | Reiterated: Buy | $18 | $12.23 | +47.24% | 22 | May 14, 2026 | |
| ATAI AtaiBeckley | Reiterated: Buy | $15 | $4.29 | +249.65% | 21 | May 13, 2026 | |
| VYGR Voyager Therapeutics | Reiterated: Buy | $12 | $3.83 | +213.32% | 38 | May 11, 2026 | |
| DFTX Definium Therapeutics | Reiterated: Buy | $38 | $22.88 | +66.08% | 14 | May 8, 2026 | |
| STOK Stoke Therapeutics | Maintained: Buy | $60 | $31.03 | +93.36% | 16 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $24 | $10.32 | +132.56% | 15 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $32 | $21.26 | +50.52% | 51 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $200 | $155.73 | +28.43% | 41 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $21 | $10.07 | +108.54% | 2 | May 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 | $2.06 | +725.24% | 11 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 | $4.43 | +915.80% | 22 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $1.22 | +1,375.41% | 55 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $120 → $36 | $3.42 | n/a | 10 | Jun 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $75 → $12 | $1.20 | n/a | 12 | Jan 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $33.16 | n/a | 4 | Apr 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $34.61 | n/a | 9 | Jan 31, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $66 → $53 | $16.26 | n/a | 8 | Nov 9, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $35 → $19 | $12.79 | n/a | 4 | Nov 7, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $109 | $10.80 | n/a | 2 | Jun 14, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $193.31 | $7.46 | n/a | 7 | Dec 18, 2015 |
CervoMed
May 19, 2026
Reiterated: Buy
Price Target: $27
Current: $3.05
Upside: +785.25%
Biogen
May 15, 2026
Reiterated: Buy
Price Target: $245
Current: $193.08
Upside: +26.89%
Clene
May 15, 2026
Reiterated: Buy
Price Target: $50
Current: $6.57
Upside: +661.04%
GH Research
May 15, 2026
Reiterated: Buy
Price Target: $39
Current: $23.15
Upside: +68.47%
MapLight Therapeutics
May 15, 2026
Reiterated: Buy
Price Target: $35
Current: $29.46
Upside: +18.81%
COMPASS Pathways
May 14, 2026
Reiterated: Buy
Price Target: $18
Current: $12.23
Upside: +47.24%
AtaiBeckley
May 13, 2026
Reiterated: Buy
Price Target: $15
Current: $4.29
Upside: +249.65%
Voyager Therapeutics
May 11, 2026
Reiterated: Buy
Price Target: $12
Current: $3.83
Upside: +213.32%
Definium Therapeutics
May 8, 2026
Reiterated: Buy
Price Target: $38
Current: $22.88
Upside: +66.08%
Stoke Therapeutics
May 8, 2026
Maintained: Buy
Price Target: $60
Current: $31.03
Upside: +93.36%
May 7, 2026
Maintained: Buy
Price Target: $24
Current: $10.32
Upside: +132.56%
May 6, 2026
Maintained: Buy
Price Target: $32
Current: $21.26
Upside: +50.52%
May 6, 2026
Reiterated: Buy
Price Target: $200
Current: $155.73
Upside: +28.43%
May 4, 2026
Maintained: Buy
Price Target: $21
Current: $10.07
Upside: +108.54%
Apr 14, 2026
Reiterated: Buy
Price Target: $17
Current: $2.06
Upside: +725.24%
Mar 6, 2026
Reiterated: Buy
Price Target: $45
Current: $4.43
Upside: +915.80%
Sep 5, 2025
Reiterated: Buy
Price Target: $18
Current: $1.22
Upside: +1,375.41%
Jun 12, 2024
Downgraded: Hold
Price Target: $120 → $36
Current: $3.42
Upside: n/a
Jan 28, 2022
Downgraded: Hold
Price Target: $75 → $12
Current: $1.20
Upside: n/a
Apr 9, 2018
Maintained: Hold
Price Target: n/a
Current: $33.16
Upside: n/a
Jan 31, 2017
Upgraded: Buy
Price Target: n/a
Current: $34.61
Upside: n/a
Nov 9, 2016
Reiterated: Buy
Price Target: $66 → $53
Current: $16.26
Upside: n/a
Nov 7, 2016
Reiterated: Sell
Price Target: $35 → $19
Current: $12.79
Upside: n/a
Jun 14, 2016
Reiterated: Sell
Price Target: $109
Current: $10.80
Upside: n/a
Dec 18, 2015
Maintained: Buy
Price Target: $193.31
Current: $7.46
Upside: n/a